Acceleron terminates drug candidate following facioscapulohumeral muscular dystrophy failure
pharmafile | September 17, 2019 | News story | Manufacturing and Production, Research and Development | Acceleron, pharma, trial failure
Acceleron Pharma has seen its stock fall by almost 4% after it unveiled new Phase 2 data confirming that its investigational therapy ACE-083 failed to meet its functional secondary endpoints in the treatment of facioscapulohumeral muscular dystrophy (FSHD).
The trial results showed that the therapy actually successfully achieved its primary endpoint, demonstrating a robust, statistically significant increase in mean total muscle volume, but this failed to translate into statistically significant improvement in functional tests.
Thus, Acceleron confirmed it would be moving to terminate its clinical trial programme investigating ACE-083 in FSHD.
“We are certainly disappointed with these results. As we have stated consistently, for ACE-083 to become an important new therapy for patients with FSHD, it would have to deliver a meaningful functional benefit on top of an ability to grow muscle,” said Habib Dable, President and Chief Executive Officer of Acceleron. “Unfortunately, in this case, the data show no evidence of such a benefit and, therefore, do not support further development of ACE-083 for FSHD. We’re grateful to the patients, families, caregivers, and investigators who participated in this research.
“We now look toward the first quarter of next year, when we expect topline results from the placebo-controlled Phase 2 trial of ACE-083 in patients with Charcot-Marie-Tooth disease, a neuromuscular disorder of different pathophysiology.”
Matt Fellows
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …